Zacks Research Has Weak Outlook for Danaher FY2025 Earnings

Danaher Corporation (NYSE:DHR) – Research analysts at Zacks Research decreased their FY2025 earnings estimates for Danaher in a research report issued on Wednesday, January 7th. Zacks Research analyst Team now forecasts that the conglomerate will post earnings of $7.70 per share for the year, down from their prior forecast of $7.71. The consensus estimate for Danaher’s current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Danaher’s Q4 2025 earnings at $2.13 EPS, Q3 2027 earnings at $2.23 EPS and FY2027 earnings at $9.20 EPS.

Other analysts have also recently issued reports about the stock. Guggenheim lifted their price objective on shares of Danaher from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Friday, January 2nd. HSBC boosted their target price on shares of Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, December 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Danaher in a research note on Monday, December 29th. Bank of America lowered their target price on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Finally, Wells Fargo & Company lifted their price target on Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Twenty-one equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $249.92.

Danaher Trading Down 0.3%

Shares of NYSE:DHR opened at $234.92 on Friday. Danaher has a 52-week low of $171.00 and a 52-week high of $258.23. The business has a 50-day moving average price of $225.31 and a 200-day moving average price of $210.22. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The stock has a market cap of $165.94 billion, a price-to-earnings ratio of 48.44, a PEG ratio of 4.19 and a beta of 0.89.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.71 EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DHR. Vanguard Group Inc. increased its stake in Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock worth $12,004,424,000 after buying an additional 788,499 shares in the last quarter. Capital International Investors boosted its stake in shares of Danaher by 1.9% in the third quarter. Capital International Investors now owns 16,758,240 shares of the conglomerate’s stock worth $3,318,926,000 after acquiring an additional 312,951 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Danaher by 0.6% during the second quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock worth $2,697,800,000 after purchasing an additional 81,670 shares in the last quarter. Norges Bank acquired a new position in Danaher in the 2nd quarter valued at $1,979,503,000. Finally, Generation Investment Management LLP lifted its holdings in Danaher by 34.0% in the 3rd quarter. Generation Investment Management LLP now owns 6,654,666 shares of the conglomerate’s stock valued at $1,319,354,000 after purchasing an additional 1,689,020 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 3,298 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares in the company, valued at approximately $4,702,593. This represents a 13.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 30,248 shares of company stock valued at $6,609,663 in the last three months. 11.10% of the stock is currently owned by company insiders.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a $0.32 dividend. The ex-dividend date is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.5%. Danaher’s payout ratio is 26.39%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.